PIONEER 6

What is PIONEER 6?

Cardiovascular safety for oral semaglutide in type 2 diabetes at high CV risk (Husain et al., NEJM 2019), showing noninferiority for MACE.

It settles one point: swallowing the drug does not cost you the cardiovascular safety profile of injecting it.

Related reading: PIONEER 6: Cardiovascular Safety for the Tablet

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where PIONEER 6 comes up on this site

Other terms under trial

• SURMOUNT-5
• SURMOUNT-2
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• REWIND
• STEP-HFpEF
• EXSCEL
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Where the evidence lives

• The full GLP-1 glossary (150 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers